New study sheds light on how immune cells may work together to drive MS
April 1, 2022
Several therapies approved to treat MS (such as Ocrevus and Kesimpta) work by targeting a molecule on the surface of B cells called CD20. Researchers at University Medicine Göttingen, Germany, recently showed that another type of immune cell – T cells – may actually be grabbing CD20 from B cells and causing inflammation and damage. When this team transferred these T cells into mice with MS-like disease, the disease worsened; when they eliminated the cells, disease improved.
Further research will look at the interaction between T cells and B cells more closely, and whether current therapies are working by causing depletion of B cells, or of these CD20-carrying T cells. Understanding these factors can lead to more effective and better-tolerated therapies for MS. This study was partly funded by the National MS Society.
Read more from Science News
Read the abstract in Science Translational Medicine
Multiple sclerosis is an unpredictable disease of the central nervous system. Currently there is no cure. Symptoms vary from person to person and may include disabling fatigue, mobility challenges, cognitive changes, and vision issues. An estimated 1 million people live with MS in the United States. Early diagnosis and treatment are critical to minimize disability. Significant progress is being made to achieve a world free of MS.
The National MS Society, founded in 1946, is the global leader of a growing movement dedicated to creating a world free of MS. The Society funds cutting-edge research for a cure, drives change through advocacy and provides programs and services to help people affected by MS live their best lives. Connect to learn more and get involved: nationalMSsociety.org, Facebook, X, formerly known as Twitter, Instagram, YouTube or 1-800-344-4867.